Francis A. Farraye, MD
Adjunct Professor, Medicine
Biography
Dr. Farraye is a Senior Associate Consultant in the Section of Gastroenterology and Hepatology at the Mayo Clinic in Jacksonville Florida where he co-directs the Inflammatory Bowel Disease Center. Prior to relocating in 2019, he was Clinical Director in the Section of Gastroenterology and the Inflammatory Bowel Disease Center at Boston Medical Center. At Chobanian and Avedisian School of Medicine, he was Professor of Medicine. Dr. Farraye earned his medical doctorate from the Albert Einstein College of Medicine in New York and his master’s degree in Epidemiology from the Harvard School of Public Health.
Dr. Farraye’s clinical interests are in the care of patients with inflammatory bowel disease. He is currently investigating C. difficile infection in IBD patients, the management and diagnosis of dysplasia and cancer in patients with IBD; social media use and health literacy in IBD patients; hepatitis B vaccination efficacy in patients with IBD; and subclinical hepatic fibrosis in patients with IBD.
A frequent speaker and invited lecturer on topics on the diagnosis and management of inflammatory bowel disease, Dr. Farraye has authored or co-authored over 450 original scientific manuscripts, book chapters, reviews, and abstracts. He is the series editor for the text Curbside Consultations in Gastroenterology and co-edited the text, Curbside Consultation in Inflammatory Bowel Disease and Gastrointestinal Emergencies. His books for patients include Questions and Answers about Ulcerative Colitis, Questions and Answers about Crohn’s Disease and Ulcerative Colitis for Dummies.
Dr. Farraye is a Fellow of the American Society of Gastrointestinal Endoscopy, American Gastroenterological Association and the American College of Gastroenterology. He has served on numerous national and international committees including as a member of the ACG Board of Trustees. He is co-chair of the Crohn’s and Colitis Foundation Membership Committee and a member of the Chapter Medical Advisory Committee for the New England Crohn’s and Colitis Foundation and a past chairman. The New England Crohn’s and Colitis Foundation named Dr. Farraye Humanitarian of the Year in 2003. In 2009, the ACG awarded Dr. Farraye the William Carey Award for service to the college. Dr. Farraye has been recognized as “Top Doctor” in Gastroenterology by Boston Magazine and U.S. News and World Report since 2010.
Other Positions
- Member, Center for Regenerative Medicine, Boston University
- Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
Education
- Albert Einstein College of Medicine, MD
- Harvard School of Public Health, MSc
- Stony Brook University, BS
Publications
- Published on 4/3/2024
Karime C, Farraye FA, Hashash JG. Use of Immune Checkpoint Inhibitors in Patients With Inflammatory Bowel Disease After Ileal Pouch-Anal Anastomosis. Inflamm Bowel Dis. 2024 Apr 03; 30(4):681-685. PMID: 37260345.
Read at: PubMed - Published on 3/28/2024
Hashash JG, Yu Ci Ng F, Farraye FA, Wang Y, Colucci DR, Baxi S, Muneer S, Reddan M, Shingru P, Melmed GY. Inter- and Intraobserver Variability on Endoscopic Scoring Systems in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2024 Mar 28. PMID: 38547325.
Read at: PubMed - Published on 3/21/2024
Smith RA, Desai A, Barnes EL, Hayney M, Kochhar GS, Hashash JG, Farraye FA, Caldera F. Patients With Inflammatory Bowel Disease Are at Increased Risk of Hospitalization Due to Respiratory Syncytial Virus. Am J Gastroenterol. 2024 Mar 21. PMID: 38318981.
Read at: PubMed - Published on 2/17/2024
Brenner EJ, Weaver KN, Zhang X, Kastl AJ, Strople JA, Adler J, Dubinsky MC, Bousvaros A, Watkins R, Dai X, Chen W, Cross RK, Higgins PDR, Ungaro RC, Bewtra M, Bellaguarda EA, Farraye FA, Chun KY, Zikry M, Bastidas M, Firestine A, Craig RG, Boccieri ME, Long MD, Kappelman MD. Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2024 Feb 17. PMID: 38369224.
Read at: PubMed - Published on 2/14/2024
Kastl AJ, Weaver KN, Zhang X, Strople JA, Adler J, Kelsen JR, Dubinsky MC, Bousvaros A, Watkins R, Dai C, Cross RK, Higgins PDR, Ungaro R, Bewtra M, Bellaguarda EA, Farraye FA, Chun K, Zikry M, Bastidas M, Boccieri ME, Firestine A, Long MD, Kappelman MD. Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2024 Apr; 78(4):871-877. PMID: 38356293.
Read at: PubMed - Published on 2/13/2024
Caldera F, Rolak S, Farraye FA, Necela BM, Cogen D, Zona EE, Schell TL, Ramirez OR, Almasry M, Chun K, Hayney MS, Knutson KL. Higher and Sustained Cell-Mediated Immune Responses after Three Doses of mRNA COVID-19 Vaccine In Patients with Inflammatory Bowel Disease on Anti-TNF Therapy. Clin Transl Gastroenterol. 2024 Feb 13. PMID: 38349178.
Read at: PubMed - Published on 2/8/2024
Odah T, Karime C, Hashash JG, Farraye FA. Nintedanib-Induced Colitis Can Mimic Inflammatory Bowel Disease. ACG Case Rep J. 2024 Feb; 11(2):e01282. PMID: 38333722.
Read at: PubMed - Published on 2/1/2024
Karime C, Crosby S, Bhat S, Hashash JG, Farraye FA. Rapid Adoption of Pneumococcal 20-Valent Conjugate Vaccination in Adult Patients With Inflammatory Bowel Disease: An Analysis One Year After Availability. J Clin Gastroenterol. 2024 Feb 01; 58(2):207-209. PMID: 38047595.
Read at: PubMed - Published on 2/1/2024
Farraye FA. Reviewing Recommendations for Vaccines and Health Care Maintenance in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2024 Feb; 20(2):115-118. PMID: 38414913.
Read at: PubMed - Published on 1/24/2024
Siu RK, Karime C, Hashash JG, Kinnucan J, Picco MF, Farraye FA. Improved Outcomes Associated With Teduglutide Use in Patients With Both Short Bowel Syndrome and Crohn's Disease. Crohns Colitis 360. 2024 Jan; 6(1):otae007. PMID: 38352117.
Read at: PubMed
View 464 more publications: View full profile at BUMC